Detalles de la búsqueda
1.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178155
2.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830573
3.
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Eur J Cancer
; 81: 151-160, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28624696
4.
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
NPJ Breast Cancer
; 3: 4, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28649644
5.
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Oncotarget
; 7(47): 77358-77364, 2016 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27764800
Resultados
1 -
5
de 5
1
Próxima >
>>